Abstract. Epigenetically-mediated gene dysregulation is a common feature associated with human pituitary tumorigenesis. The mechanisms leading to these changes, however, remain largely unknown. In this review, we examine changes responsible for DNA and histone modifications as independent, butpotentially interrlated modes of communication effecting chromatin remodeling. The dynamic properties of the enzymes involved in these reactions is highlighted. We use the fibroblast growth factor receptor 2 (FGFR2) as a model through which the p53-regulating melanoma-associated antigen (MAGE) system is governing in pituitary cells. The pathogenetic and potential therapeutic implications are discussed.
PITUITARY tumors comprise nearly 10% of surgically removed intracranial neoplasms. They cause morbidity through invasive growth into surrounding brain and bony structures. Pituitary tumorigenesis infrequently involves intragenic mutations of oncogenes or tumor suppressor genes [1, 2] . Increasing evidence, however, suggests that signals implicated in pituitary organogenesis may be equally relevant to the tumorigenic processes with significant contributions from the bone morphogenic protein (BMP), Wnt, and fibroblast growth factor (FGF) families [3, 4] .
The Role of fibroblast growth factors in the pituitary
There are currently 22 recognized members of the FGF ligand family and their receptors are encoded by four independent genes each giving rise to multiple isoforms [5] . The FGFR2 gene is alternatively spliced to generate FGFR2-IIIb (also referred to as KGFR), an isoform containing the second half of the third Ig-like domain encoded by exon 7, that binds FGF1, FGF3, FGF7, and FGF10 with high affinity [6, 7] . In contrast, the FGFR2-IIIc isoform in which the second half of the third Ig-like domain is encoded by exon 8, does not bind FGF7 or FGF10 [8, 9] . FGFR2-IIIb expression is restricted mainly to epithelial cells, whereas FGFR2-IIIc is more frequently present in mesenchymal cells [10] .
Altered FGF receptor signaling in pituitary tumors
FGF signaling is critical in pituitary development. Deletion of the FGFR2-IIIb isoform leads to failure of pituitary development [11] . Mid-gestational expression of a soluble dominant-negative FGFR results in severe pituitary dysgenesis [12] . Similarly, multiple lines of evidence have supported the involvement of members of the FGF/FGFR family in pituitary tumorigenesis. Selected FGF ligands are overexpressed in pituitary tumors [13] . Moreover, the human endogenous FGF antisense gene (GFG) is expressed in the normal pituitary where it restricts cell proliferation, and its expression is reduced in pituitary tumors [14] .
Alternative transcription initiation and oncogenic FGFR4 (ptd-FGFR4)
We have previously found evidence of altered expression of two members of the FGFR family in pitu-itary tumors [15] . We noted that FGFR4 is Nterminally truncated to yield a pituitary tumor-derived FGFR4 (ptd-FGFR4) [15, 16] as a result of alternative transcription initiation from a cryptic intronic promoter [17, 18] . This oncogene displaces N-cadherin from the cell membrane to interfere with normal cell adhesion [19] . We also observed that FGFR2-IIIb is expressed in the normal pituitary but significantly down-regulated in pituitary tumors [15] . Forced expression of FGFR2-IIIb arrests pituitary tumor cell cycle progression [20] .
FGFR2 is epigenetically silenced in the pituitary
Given the recognized role for FGFR2 in the development of the anterior pituitary gland [1] and the common theme of epigenetic silencing in human pituitary tumorigenesis [21] , we examined putative target genes of FGFR2-IIIb using cDNA microarray profiling. Although the expression of the majority of genes was not significantly altered, we found that members of the cancer/testis-melanoma associated antigen (MAGE-A) were down-regulated by nearly 60 fold [22] . These findings provided the basis for examining whether MAGE-A3 is expressed in human pituitary tumors where FGFR2 is down-regulated and whether this relationship is governed through inter-dependency on histone modifications. This will be the subject of this review.
The importance of histone modifications in gene control
The assembly of DNA into a compact structure termed chromatin is essential for packaging the genome into the relatively confining regions of the cell nucleus. The nucleosome, the basic unit of chromatin, consists of ~200 bp of DNA coiled twice around an octamer, which is composed of dimers of the core histones (H1-4). In a cell, the nucleosome is further compacted into a higher-order structure. Such compaction can result in the regulatory DNA elements of genes being inaccessible to regulatory proteins or transcription factors, which interfere with gene expression resulting in gene silencing (Fig. 1) . One important way of altering or modifying histones involves covalent modifications through phosphorylation or ribosylation. However, acetylation and methylation represent the most widely studied dynamic processes. In particular, Acetylation (Ac) of specific lysine (K) residues on histone H4 and methylation (Me) of lysine 9 (K9) on H3 can be found at inactive gene loci. Alternatively, acetylation on K9 and K14 of H3, methylation on K4 of H3, or acetylation on K5 of H4 can be identified at gene loci that are either active or have the potential to become activated. Increasingly dedicated enzymes involved in specific dynamic histone modifications are being unmasked.
The melanoma associated antigen -3 (MAGE-A3) is a target of FGFR2
We found that MAGE-A3 is reciprocally expressed in tumors where FGFR2-IIIb is absent. These data validate gene profiling evidence that the putative oncogene MAGE-A3 is indeed a target of FGFR2 action [22] . We also found that MAGE-A3 expression is intimately linked with the frequency and degree of promoter hypomethylation, particularly in tumors from female subjects. This is consistent with the induction of MAGE-A3 by estrogen through histone modification. This latter action abrogates the effect of FGFR2-IIIb, highlighting MAGE-A3 as a point of signaling integration between opposing forces (Fig. 2) .
We have previously noted the co-expression of FGFR2-IIIb and FGFR2-IIIc isoforms in normal human pituitary cells [15] . Pharmacologic methylation inhibition resulted in mainly FGFR2-IIIb reexpression with minimal impact on the IIIc isoform in pituitary cells [20] . Similar findings of FGFR2-IIIb isoform silencing have been previously noted in other neoplasms [28] [29] [30] . Re-expression of FGFR2-IIIb results in potent tumor growth inhibition with enhanced apoptosis [31] . This effect has been ascribed to the ability of FGFR2-IIIb to sequester the FGFR substrate (FRS2) [32] diverting it away from other competing FGFR signal [22] . Consistent with this model, FGFR2-IIIb signalling using its selective ligand FGF7 results in diminished pituitary tumor cell cycle progression [20] . This effect was recapitulated here through down-regulation of MAGE-A3 which resulted in p53 and p21 induction, providing further functional evidence implicating MAGE-A3 as an important down-stream mediator of FGFR2-IIIb signaling.
The melanoma-associated antigen family (MAGE)
MAGE-A3 and -A6 genes are members of the MAGE-I family that includes the MAGE-A, -B, and -C subfamilies [33] . The MAGE-I family consists of a number of chromosome X-clustered genes, which are expressed mainly in testicular germ cells, placenta, and a variety of malignant tumors, resulting in their designation as Cancer/Testis antigens [33] [34] [35] [36] [37] . Our new data describe the presence of MAGE-A3 transcripts in pituitary tumors. Further, we found that MAGE-A3 can regulate the transcription of p53, consistent with one previous report implicating MAGE-A2 in p53 regulation [27] . Moreover, MAGE-A3 down-regulation resulted in p53 and p21 accumulation, consistent with the putative oncogenic functions of this cancer antigen. It is noteworthy that while p53 is not intragenically mutated in pituitary adenomas, variable levels of p53 protein accumulation have been reported in these tumors [38] . Our findings, therefore, suggest that MAGE-A3 may represent an important candidate gene responsible for p53 dysregulation in pituitary tumors.
MAGE-A3 is regulated through epigenetic histone modifications as well as DNA methylation
Our data also point to several putative mechanisms underlying the loss and gain of expression of the MAGE-A3 in normal and neoplastic pituitary cells respectively. Previous reports implicated CpG methylation status in the 5' region of MAGE-A genes in the process of regulation [39, 40] . In line with this prediction, we found that the MAGE-A3 promoter is heavily methylated in normal human pituitary cells, resulting in lack of expression in this tissue. In contrast, we found the MAGE-A3 promoter to be hypomethylated in pituitary tumors. These findings provide further evidence supporting epigenetic regulation through DNA methylation as a mechanism behind the ectopic expression of putative oncogenes such as MAGE-A3 in human pituitary tumors. Our current study also shows that MAGE-A3 is generally down-regulated where FGFR2-IIIb is expressed. These findings and our previous data [22] suggest that FGFR signaling can epigenetically modulate MAGE-A3 gene expression, providing evidence for an interregulatory loop. Taken together the current evidence provides further validation for the role of FGFR2-IIIb signaling, a putative tumor-retarding factor [20, 31] , in the epigenetic modifications leading to MAGE-A3 down-regulation. Conversely, estrogen treatment, a potent stimulator of pituitary tumor progression [2, 41] was associated with MAGE-A3 induction. This latter effect was demonstrated to also occur through histone modifications.
Epigenetics as a broad mechanism responsible for gene silencing in pituitary tumors
An emerging theme from studies of human pituitary tumors is altered epigenetic control more frequently than intragenic mutations, loss-of-heterozygosity, or gene rearrangements [42] . Consistent with its wellrecognized impact on pituitary neoplasia in genetically deficient mice [43] , the Rb tumour suppressor gene is principally silenced through CpG island methylation in neoplastic human pituitary cells [44] [45] [46] . No inactivating mutations have been identified within the Rb promoter in pituitary tumors that are deficient of this protein [47] . Similarly, mice lacking p27 kip1 have an increased propensity to develop multi-organ neoplasia, including pituitary tumors [48] , and protein levels of this CDKI are reduced in human pituitary adenomas however the p27 kip1 gene is not mutated [49, 50] . Expression of GADD45γ, a member of a growth arrest and DNA damage-inducible gene family, is reduced in pituitary tumors [51] through CpG island promoter methylation [52] . Similarly, the Ras-association domain family 1A gene (RASSF1A), originally cloned from the lung tumor locus at 3p21.3, is frequently inactivated through promoter hypermethylation in pituitary tumors [53] . Additionally, MEG3, a human homolog of the mouse maternally imprinted Gtl2 gene, is also down-regulated in human pituitary tumors through 5' promoter hypermethylation [54] . MAGE-A3 is another X-chromosome-linked gene which has been shown to be epigenetically imprinted [26] . Consistent with this prediction, we identified a greater frequency of MAGE-A3 expression and promoter hypomethylation in pituitary tumors as a group and more so in female subjects. Interestingly, estrogen potently up-regulates MAGE-A3, and consistent with the sensitivity of the MAGE-A3 promoter to histone modifications, estrogen induction of MAGE-A3 was associated with enhanced histone acetylation and concomitant reduction in histone methylation. More significantly, we found that the effects of estrogen and FGF7/FGFR2-IIIb impose on reciprocal histone modifying networks to regulate MAGE-A3.
Histone modifications as a specific control mechanism in pituitary tumors
Taken together, our recent studies identify a reciprocal profile of FGFR2-IIIb and MAGE-A3 expression in the normal and neoplastic pituitary. While FGFR2-IIIb plays a growth-inhibitory tumor-suppressive role [31] , MAGE-A3 is considered to have growth-promoting oncogenic functions [27, 55] . Our data highlight MAGE-A3 as a downstream target of FGFR2-IIIb. They also point to the significance of DNA hypomethylation as well as histone modifications in the expression of putative oncogenic signals. Given the recognized importance of DNA hypermethylation in pituitary tumors, our findings underscore the complex network of epigenetic changes in the control over the balance of signals with opposing functions. 
